• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    R

    Rainier Clinical Research Center

    EST. 1991
    29论文总数
    2,447引用总数

    论文量&引用量时间轴

    机构学者

    论文(29)

    年份
    起
    –
    止
    排序
    1Safety and Glycemic Outcomes of the MiniMed 780G System with a Disposable All-in-One Sensor.
    Laura M Nally,Jennifer L Sherr,Satish K Garg,Brynn E Marks,Lori M Laffel,Catherine Pihoker, Siham D Accacha, James R Thrasher,M Jennifer Abuzzahab, John H Reed,Laya Ekhlaspour, Sonali Belapurkar,

    INTRODUCTION:The present study assessed the impact of the disposable Simplera Sync™ sensor with the MiniMed™ 780G (MM780G) advanced hybrid closed-loop (AHCL) system on type 1 diabetes (T1D) glycemic metrics, insulin delivery, and safety. MATERIALS AND METHODS:Youths (aged 7-17 years) and adults (aged 18-80 years) with T1D were enrolled in this single-arm, nonrandomized study at 24 sites in the United States. Participants began with an ∼2-week run-in period where hybrid closed-loop (HCL; auto basal only) or open-loop insulin delivery was used, followed by an ∼3-month study period with AHCL activated. Glycemic outcomes and insulin delivery during the last 6-7 weeks of the study, when settings were optimized at investigator's discretion, were compared with the run-in. Glycemic outcomes with the use of recommended optimal settings (ROS, 100 mg/dL glucose target with a 2-h active insulin time) were explored. RESULTS:Time in automation was high (>93%) and mean time in range (TIR) increased from 54.4% ± 15.7% to 71.4% ± 9.9% (P < 0.001) in youths and from 66.5% ± 12.6% to 80.2% ± 8.1% (P < 0.001) in adults, primarily due to reduced time above range. Youths had a slight increase in time below range (TBR <70 mg/dL) from 1.6% ± 1.7% to 1.9% ± 1.4% (P < 0.001), while adults had no significant difference in TBR. For ROS users, TIR was 74.7% ± 9.3% in youths and 83.8% ± 7.4% in adults. Throughout the study ∼60% of total daily insulin dose was automated (auto basal and auto correction) in both cohorts. There were two cases of severe hypoglycemia and one episode of diabetic ketoacidosis (not related to the device). CONCLUSIONS:MM780G use with the Simplera Sync sensor is safe and demonstrated improved glycemic outcomes in both pediatric and adult participants with T1D, compared with the run-in period.

    2026Diabetes technology & therapeutics(2026)引用:2
    引用
    AI阅读
    加入学术空间
    2A Phase 2 Study of XP-8121: Once-Weekly Subcutaneous Levothyroxine Sodium for the Treatment of Hypothyroidism in Adults.
    Valentina Conoscenti, Robbie Huang, Diane Rudisill, Richard Fitch, Frances Broyles, Matthew David Ettleson,Antonio C Bianco

    BACKGROUND:The standard of care for hypothyroidism treatment worldwide is daily oral levothyroxine (LT4) sodium. Limitations associated with daily oral administration highlight the need for alternative formulations to address challenges in maintaining euthyroidism. XP-8121 (LT4 sodium for subcutaneous [SC] administration) is a ready-to-use, liquid formulation of LT4 intended for once-weekly administration, offering an alternative hormone replacement approach by bypassing the gastrointestinal tract. This study assessed the safety, tolerability, and target dose conversion factor from oral LT4 to XP-8121 SC in adult participants. PARTICIPANTS AND METHODS:This Phase 2, multicenter, nonrandomized, open-label, single-arm, self-controlled study (NCT05823012) evaluated XP-8121 SC in 46 adults with hypothyroidism receiving a consistent dose of oral LT4 for at least 3 months prior to screening, with documented normal thyrotropin (TSH) levels at least 3 months prior to screening and normal free thyroxine (fT4) at screening. The weekly XP-8121 SC dose was initiated at 50% of the target dose and titrated every 2 weeks for up to 8 weeks based on individual response using fT4 trough concentrations. Following titration, participants continued the established dose during a 4-week maintenance period. RESULTS:Of the 46 participants enrolled, 39 completed the study. The majority were female (37; 80.4%) and identified as White (44; 95.7%). The final dose conversion factor point estimate ranged from 4.02 (90% confidence interval [CI]: 3.79-4.27) to 4.24 (90% CI: 4.06-4.42), supporting a conversion factor of approximately four times the daily oral LT4 dose when transitioning to XP-8121 SC. Although participants were initially underdosed during titration, TSH normalization was observed in 79.5% and fT4 normalization in 100% among those who completed the study on a consistent dose (unchanged for 6 weeks) at the end of maintenance. Overall, 78 treatment-emergent adverse events (TEAEs) were reported in 30 participants (65.2%) who received at least one dose of XP-8121 SC; fatigue (21.7%) and injection-site pain (10.9%) were the most common TEAEs. A majority of participants who completed the study reported higher satisfaction, convenience, and perceived effectiveness with once-weekly XP-8121 SC and expressed preference over daily oral LT4. CONCLUSIONS:Once-weekly XP-8121 SC was generally well-tolerated in all treated participants and supported a dose conversion factor of four times the daily oral LT4 dose.

    2026Thyroid official journal of the American Thyroid Association(2026)
    引用
    AI阅读
    加入学术空间
    3Impact of Ascorbic Acid and Exercise on Accuracy of a Glucose Monitoring System with GDH-FAD Technology in Adult Patients with Type 1 Diabetes Mellitus: A Double-Blinded, Randomized Trial
    Ronald Brazg, Tina Mitchell, Jiangfeng Fei, Jiyun Zheng, Fei Gao, Ao Gao, Siting Zhu,Frank Flacke,Leon Shi,Poul Strange

    The performance of a new continuous glucose monitoring system (CGM) with flavin adenine dinucleotide-dependent glucose dehydrogenase (GDH-FAD) technology in adults with type 1 diabetes mellitus (T1DM) was assessed, with a focus on the impact of ascorbic acid and exercise on the accuracy of glucose measurements relative to Yellow Springs Instrument (YSI) 2300 control. Adults with T1DM aged 18–65 years using a stable glucose management treatment regimen for at least 3 months with multiple daily injections or continuous subcutaneous insulin infusion participated in this study at a single center. Participants attended a screening visit and three in-clinic visits for frequent blood sampling with blood glucose measurements using YSI measurements as the reference measurement as endorsed by the Food and Drug Administration (FDA). Participants had two meals at each clinic visit leading to pronounced glucose excursions. On the second and third in-clinic visits, participants performed moderate exercise in between the two meals and were randomized to receive 1000 mg of ascorbic acid orally at either of those visits. Accuracy evaluation included the proportion of CGM values within 15

    2026Diabetes Therapy(2026)
    引用
    AI阅读
    加入学术空间
    4Simplified Meal Bolus Strategies with Control-IQ+ Automated Insulin Delivery Are Safe and Effective in Adults with Type 2 Diabetes.
    Carol J Levy,Lauren Kanapka, Sue A Brown, Sheryl Marks,Tamara Spaic, Devin W Steenkamp, Virginia S Lu, Peter Zhao,John W Lum,Roy W Beck,Jordan E Pinsker, 2IQP Study Group

    OBJECTIVE:To characterize simplified meal bolus strategies in adults with insulin-treated type 2 diabetes using automated insulin delivery (AID). RESEARCH DESIGN AND METHODS:In the 2IQP study, a 13-week randomized, controlled trial comparing Control-IQ+ AID to continuation of pre-study insulin regimen with continuous glucose monitoring, 201 participants in the AID arm were classified by meal bolus strategy. Glycemic outcomes were compared to baseline. RESULTS:68 participants' meal bolus strategies (33.8%) were classified as Carbohydrate Counting, 79 (39.3%) were classified as Preset Carbohydrate Amounts, 27 (13.4%) were classified as Fixed Insulin Doses, and 27 (13.4%) as Other Methods. All bolus strategies were associated with similar, significant improvements in HbA1c from baseline: -0.9% for Carbohydrate Counting (P < 0.001), -1.1% for Preset Carbohydrate Amounts (P < 0.001), -0.8% for Fixed Insulin Doses (P < 0.001), and -0.9% for Other Methods (P = 0.003). Hypoglycemia rates were low at baseline and remained low for all bolus strategies. As participants gained experience with the Control-IQ+ AID system, more participants opted to use a simplified bolus strategy in the second half of the study compared with the first half (63% vs. 52%). CONCLUSION:Simplified bolus strategies worked well for adults with type 2 diabetes using Control-IQ+ in the 2IQP trial. All bolus strategies led to substantial HbA1c improvements, without safety concerns.

    2025Diabetes technology & therapeutics(2025)引用:2
    引用
    AI阅读
    加入学术空间
    5A Multicenter Study of an Investigational Extended Wear Insulin Infusion Set in Adults with Type 1 Diabetes.
    Rayhan A Lal,John W Lum, Zachariah W Reed,Davida Kruger, John Chip Reed,Ruth S Weinstock,Anders L Carlson,Yogish C Kudva, David Liljenquist,Erin C Cobry, Camilla M Levister,Grazia Aleppo,

    Objective: To evaluate the function and safety of the SteadiSet™ infusion set over a continuous 7-day wear period in adults with type 1 diabetes. Research Design and Methods: Participants used a SteadiSet infusion set with a t:slim X2™ insulin pump with Control-IQ™ technology, and either insulin aspart or insulin lispro, for a target of 7 days for 12 consecutive wear periods. Each set removed before 7 days was adjudicated by an independent committee to assess the cause of early removal and to determine whether criteria for primary or key secondary endpoints were met. Results: There were 260 participants who inserted 3028 infusion sets. For the primary endpoint, the Kaplan-Meier 7-day survival estimate was 95% (95% CI 94% to 96%). For the key secondary endpoint, which expanded the reasons for a failed infusion set, the Kaplan-Meier 7-day survival estimate was 84% (95% CI 82% to 86%). For both endpoints, the P value was <0.001 compared with a prespecified survival rate of 75%. Time-in-range 70-180 mg/dL (TIR) increased through day 3 of set wear and then decreased through day 7, with the average TIR being 70.6% over the entire wear period across all infusion sets, including those that failed. An increase in total daily insulin was observed from day 4 through day 7. Conclusions: The 7-day survival of the SteadiSet infusion set was very high for the primary endpoint and at an acceptable level with respect to early removal for any reason related to the device.

    2025Diabetes technology & therapeutics(2025)引用:1
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 29 篇论文

    合作机构(71)

    Diablo Clinical Research合作论文 6
    斯坦福大学合作论文 3
    华盛顿大学合作论文 3
    伊利诺伊理工学院合作论文 2
    科罗拉多州立大学合作论文 2
    耶鲁大学合作论文 2
    密歇根州立大学合作论文 2
    南非大学合作论文 2
    Atlanta Diabetes Associates合作论文 2
    Sansum Diabetes Research Institute合作论文 2

    机构统计